What other stocks do shareholders of Allos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allos Therapeutics investors own include E-House (China) Holdings Limite (EJ) , DryShips (DRYS) , Depomed (DEPO) , Hongli Clean Energy Technologie (CETC) , (CASC) (CASC) , Alexco Resource (AXU) , AXT (AXTI) , AudioCodes (AUDC) and Amtech Systems (ASYS) .

NASDAQ:ALTH

Allos Therapeutics (ALTH) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free ALTH Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Allos Therapeutics alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Allos Therapeutics Stock (NASDAQ:ALTH)

Allos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

ALTH Stock News Headlines

November 2, 2021 | finance.yahoo.com

Laronde Expands Board of Directors with Leading Pharmaceutical Executives

See More Headlines

Receive ALTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:ALTH
CUSIP: N/A
CIK: 1097264
Web: www.allos.com
Phone: +1-303-4266262
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

ALTH Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Allos Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allos Therapeutics investors own include E-House (China) Holdings Limite (EJ), DryShips (DRYS), Depomed (DEPO), Hongli Clean Energy Technologie (CETC), (CASC) (CASC), Alexco Resource (AXU), AXT (AXTI), AudioCodes (AUDC) and Amtech Systems (ASYS).

This page (NASDAQ:ALTH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allos Therapeutics (ALTH) Stock Price, News & Analysis

About Allos Therapeutics Stock (NASDAQ:ALTH)

ALTH Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

ALTH Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info